Medicare Covers NanoKnife IRE for Prostate, Liver Cancer with CPT Codes in 2026
ANGO•Palmetto GBA’s final Local Coverage Determination L40205 establishes Medicare reimbursement for NanoKnife’s irreversible electroporation procedures in intermediate-risk prostate cancer and metastatic colorectal liver lesions, effective July 5, 2026. Category I CPT codes activated January 1, 2026 provide standardized billing and physician RVUs for prostate and liver IRE.
1. Medicare Coverage Framework for IRE
Palmetto GBA’s final Local Coverage Determination L40205, effective July 5, 2026, establishes Medicare coverage for irreversible electroporation with the NanoKnife System in favorable intermediate-risk prostate cancer (Gleason Score 3+4) and metastatic colorectal cancer to the liver when surgical resection or thermal ablation is unsuitable.
2. Clinical and Billing Developments
Category I CPT codes for prostate and liver IRE procedures became active on January 1, 2026, incorporating physician relative value units and standardized billing across hospital outpatient departments and ambulatory surgical centers, while patient selection criteria align with AUA, ASTRO and NCCN clinical guidelines.
3. Implications for AngioDynamics
This coverage framework and coding recognition enable treated physicians to secure reimbursement under Medicare Part A and B in Palmetto GBA jurisdictions, potentially accelerating NanoKnife adoption, expanding patient access, and supporting revenue growth for AngioDynamics in key urology and oncology markets.
